Publications scientifiques en 2025

Depuis le 31/03/2025
  1. Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study.
    Bénard-Laribière A, Pambrun E, Kouzan S, Faillie JL, Bezin J, Pariente A.
    Thorax. 2025
  2. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Boulefaa D, Bagheri H, Salvo F, Rabier MB, Geniaux H, Lepelley M, Rocher F, Mahe J, Grandvillemuin A, Thai-Van H.
    Drug Saf. 2025
  3. Ethics and clinical research: How can the Ethics Committees (CPPs) and Committees for Research Ethics (CER) evolve?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2025
  4. Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and Implications.
    Goff RL, Brice S, Contini A, Boussac M, Souche A, Belloc F, Coulombel N, Collin C, Gouverneur A, Molimard M.
    Pharmacoepidemiol Drug Saf. 2025
  5. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2025
  6. Psychoactive cocktail consumption on Reunion Island: A case report.
    Guyon J, Maillot A, Bastard S, Weisse F, Daveluy A, Mété D.
    J Anal Toxicol. 2025
  7. Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
    Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, Roustit M, Khouri C.
    Drug Saf. 2025
  8. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025
  9. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  10. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  11. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  12. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025